Overview

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Status:
NOT_YET_RECRUITING

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

anlotinib